Witnessing the stock’s movement on the chart, on Wednesday, Lexeo Therapeutics Inc (NASDAQ: LXEO) set off with pace as it heaved 3.60% to $4.6, before settling in for the price of $4.44 at the close. Taking a more long-term approach, LXEO posted a 52-week range of $1.45-$19.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -99.98%. Meanwhile, its Annual Earning per share during the time was -99.98%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 14.56%. This publicly-traded company’s shares outstanding now amounts to $33.19 million, simultaneously with a float of $22.90 million. The organization now has a market capitalization sitting at $152.70 million. At the time of writing, stock’s 50-day Moving Average stood at $3.65, while the 200-day Moving Average is $5.38.
Lexeo Therapeutics Inc (LXEO) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Lexeo Therapeutics Inc’s current insider ownership accounts for 31.02%, in contrast to 90.35% institutional ownership. According to the most recent insider trade that took place on May 16 ’25, this organization’s Chief Executive Officer sold 1,074 shares at the rate of 2.77, making the entire transaction reach 2,979 in total value, affecting insider ownership by 221,173. Preceding that transaction, on May 16 ’25, Company’s Chief Medical Officer sold 585 for 2.77, making the whole transaction’s value amount to 1,623. This particular insider is now the holder of 67,681 in total.
Lexeo Therapeutics Inc (LXEO) Earnings and Revenue Records
Lexeo Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 14.56% and is forecasted to reach -2.02 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 18.09% through the next 5 years, which can be compared against the -99.98% growth it accomplished over the previous five years trading on the market.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Trading Performance Indicators
Let’s observe the current performance indicators for Lexeo Therapeutics Inc (LXEO). It’s Quick Ratio in the last reported quarter now stands at 3.42.
In the same vein, LXEO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.31, a figure that is expected to reach -0.67 in the next quarter, and analysts are predicting that it will be -2.02 at the market close of one year from today.
Technical Analysis of Lexeo Therapeutics Inc (LXEO)
Going through the that latest performance of [Lexeo Therapeutics Inc, LXEO]. Its last 5-days volume of 0.52 million was inferior to the volume of 0.71 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 65.60% While, its Average True Range was 67.96%.
Raw Stochastic average of Lexeo Therapeutics Inc (LXEO) in the period of the previous 100 days is set at 76.83%, which indicates a major fall in contrast to 79.51% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.35 that was lower than 0.45 volatility it exhibited in the past 100-days period.
